Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07CNY
|
||||
Former ID |
DIB016518
|
||||
Drug Name |
Instiladrin
|
||||
Indication | Bladder cancer [ICD9: 188; ICD10:C67] | Phase 2 | [524056] | ||
Company |
Fkd therapies
|
||||
Target and Pathway | |||||
Target(s) | Interferon alpha 2 ligand | Target Info | Modulator | [524056] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
Regulation of autophagy | |||||
PI3K-Akt signaling pathway | |||||
Toll-like receptor signaling pathway | |||||
RIG-I-like receptor signaling pathway | |||||
Cytosolic DNA-sensing pathway | |||||
Jak-STAT signaling pathway | |||||
Natural killer cell mediated cytotoxicity | |||||
Tuberculosis | |||||
Hepatitis C | |||||
Hepatitis B | |||||
Measles | |||||
Influenza A | |||||
Herpes simplex infection | |||||
Autoimmune thyroid disease | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
Pathway Interaction Database | Downstream signaling in naï | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.